CAPR

NASDAQ open

Capricor Therapeutics

7.94 USD
▲+0.41+5.44%
盘后 8.68 0.00%
2026-11-20
市值
$441.30M
市盈率
—
EPS
-2.65
股息率
—
52 周区间
2.96 – 40.37
成交量
6.98M
Beta
0.77
目标价
27.25
52W 低 2.9652W 高 40.37
价格走势

公司简介

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and...

关联新闻